Jonathan Tobin, a partner at life science venture capital firm Brandon Capital, and Genghis Lloyd-Harris, a senior advisor at life sciences investment firm, Abingworth, have joined Cancer Research Horizons’ Ventures team as advisory investors-in-residence.
The University of Cambridge announced a new partnership with AstraZeneca and the Medical Research Council (MRC) that will establish a new state-of-the-art functional genomics laboratory at the Milner Therapeutics Institute.
Last week felt like an important milestone for the UK life science sector. As I sat in the Life Science Council in No 10 Downing Street with new Government Ministers, leaders of public institutions like the MHRA and global CEOs, I reflected that no other country in the world is putting together a working collaborative life science group like this.
The Rosalind Franklin Institute announces Professor Paul Matthews as its new Institute Director. Professor Matthews is a world class clinician scientist with over 30 years of experience working on neurodegenerative disorders.
Ian Goodwin, Director of CMC Program Design in Advanced Therapies (covering Cell and Gene Therapy services) at FUJIFILM Diosynth Biotechnologies explores the benefits of candidate and feasibility studies to AAV production.
Cancer Research Horizons, the innovation arm of Cancer Research UK, has opened nominations for its Innovation & Entrepreneurship Awards 2024, which celebrate the UK’s most enterprising efforts in oncology.
Northumberland-headquartered Merit, the UK’s leading industrialised construction and digital manufacturing specialist, has reached a significant project milestone for Moderna’s clinical laboratories project.
The Chancellor has delivered a comprehensive package of investment and support for the UK life sciences industry in his Autumn Statement. In this blog, Dr Martin Turner, Head of Policy and Public Affairs at BIA shares his reflections on key announcements.